• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

恶性淋巴瘤和实体瘤中表鬼臼毒素VM26的临床筛查

Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.

出版信息

Br Med J. 1972 Jun 24;2(5816):744-8.

PMID:4556544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1788459/
Abstract

Epipodophyllotoxin (VM 26; 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside) has been proved, in clinical screening, to be able to induce apparently complete remissions and pronounced though incomplete regressions in Hodgkin's disease, reticulosarcoma, and bladder cancer, as well as incomplete regressions in lymphosarcoma. Apparently complete regressions of malignant pleural effusions have been obtained after giving this drug systemically. It has a notable toxic action on the bone marrow.

摘要

表鬼臼毒素（VM 26；4'-去甲基表鬼臼毒素-β-D-噻吩亚甲基糖苷）在临床筛选中已被证实，能够使霍奇金病、网状细胞肉瘤和膀胱癌出现明显完全缓解以及显著但不完全消退，在淋巴肉瘤中则出现不完全消退。全身给予该药物后，恶性胸腔积液已出现明显完全消退。它对骨髓有显著的毒性作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d82a/1788459/360c8e2e4c83/brmedj02209-0033-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d82a/1788459/764f5f721604/brmedj02209-0033-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d82a/1788459/360c8e2e4c83/brmedj02209-0033-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d82a/1788459/764f5f721604/brmedj02209-0033-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d82a/1788459/360c8e2e4c83/brmedj02209-0033-b.jpg

相似文献

1
Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.恶性淋巴瘤和实体瘤中表鬼臼毒素VM26的临床筛查
Br Med J. 1972 Jun 24;2(5816):744-8.
2
Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
Br Med J. 1973 Jul 28;3(5873):199-202.
3
Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.一种新的鬼臼毒素衍生物，表鬼臼毒素，4'-去甲基-9-(4,6-O-2-亚噻吩基-β-D-吡喃葡萄糖苷)(NSC-122819)在恶性淋巴瘤和实体瘤患者中的临床研究。
Cancer Chemother Rep. 1972 Feb;56(1):71-82.
4
Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.
Eur J Cancer (1965). 1974 Feb;10(2):93-8. doi: 10.1016/0014-2964(74)90058-9.
5
[Experiences with the cytostatic podophyllin therapy].
Munch Med Wochenschr. 1967 Feb 18;108(7):378-81.
6
[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)].
Nouv Presse Med. 1974 Mar 2;3(9):521-4.
7
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
Cancer Chemother Rep. 1971 Dec;55(5):575-81.
8
[Therapeutic trials in various hematosarcomas with 4-demethylepipo=dophyllotoxin-beta D thenylidene glucoside (VM 26 or EPT)].
Nouv Presse Med. 1974 Feb 23;3(8):447-51.
9
[Internal treatment of carcinoma with the cytostatic Proresid].应用细胞抑制剂丙卡巴肼对癌症进行的内科治疗
Munch Med Wochenschr. 1966 Jan 14;108(2):112-4.
10
[Results obtained with the clinical use of adriamycin].[阿霉素临床应用所获结果]
Haematologica. 1971;56(9):343-66.

引用本文的文献

1
Teniposide: overview of its therapeutic potential in adult cancers.替尼泊苷：其在成人癌症治疗潜力的概述
Cancer Chemother Pharmacol. 1994;34 Suppl:S127-33. doi: 10.1007/BF00684876.
2
VM26: phase I and II studies.
Cancer Chemother Pharmacol. 1982;7(2-3):87-91. doi: 10.1007/BF00254527.
3
The podophyllotoxin derivatives VP16-213 and VM26.
Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.
4

本文引用的文献

1
Efficacy of cyclophosphamide in the management of reticulum cell sarcoma.环磷酰胺治疗网状细胞肉瘤的疗效。
Cancer. 1966 Oct;19(10):1386-92. doi: 10.1002/1097-0142(196610)19:10<1386::aid-cncr2820191009>3.0.co;2-k.
2
Vincristine therapy of lymphomas and chronic lymphocytic leukemia.长春新碱治疗淋巴瘤和慢性淋巴细胞白血病。
Cancer. 1970 Aug;26(2):352-9. doi: 10.1002/1097-0142(197008)26:2<352::aid-cncr2820260217>3.0.co;2-8.
3
Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids.
[Diagnostic and therapeutic procedures in Hodgkin's disease].
[霍奇金淋巴瘤的诊断与治疗程序]
Blut. 1973 Aug;27(2):105-30. doi: 10.1007/BF01632001.
5
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.替尼泊苷（VM-26）治疗转移性乳腺癌的II期评估。一项东南癌症研究组试验。
Invest New Drugs. 1988 Apr;6(1):37-9. doi: 10.1007/BF00170777.
6
Phase II study of teniposide in advanced breast cancer.替尼泊苷治疗晚期乳腺癌的II期研究。
Cancer Chemother Pharmacol. 1990;25(6):463-4. doi: 10.1007/BF00686061.
7
New cancer chemotherapy drugs in Europe.
Cancer Chemother Pharmacol. 1978;1(1):5-13. doi: 10.1007/BF00253141.
8
Antineoplastic drugs: clinical pharmacology and therapeutic use.抗肿瘤药物：临床药理学与治疗应用
Drugs. 1978 Jul;16(1):46-87. doi: 10.2165/00003495-197816010-00003.
9
New aspects of brain tumor research.
J Neurol. 1977 Mar 21;214(4):241-50. doi: 10.1007/BF00316569.
恶性淋巴瘤患者的管理：环磷酰胺与长春花生物碱的对比研究。
Cancer Res. 1968 May;28(5):811-22.